FALLOPIAN TUBE CANCER

This study tested an experimental drug called mirvetuximab soravtansine for women with recurrent ovarian, peritoneal, or fallopian tube cancers that had previously responded well to platinum-based chemotherapy. The drug is designed like a 'smart bomb' to target and kill cancer ce…

This study tested an experimental drug called RC88 in women whose ovarian, fallopian tube, or primary peritoneal cancer had returned and was no longer responding to standard platinum-based chemotherapy. The main goals were to see if the drug could shrink tumors, how long the bene…

This study tested a new drug called ZN-c3, both by itself and combined with an existing drug (niraparib), for women with advanced ovarian cancer that had stopped responding to platinum chemotherapy. The main goals were to find safe doses and see if the treatments could shrink tum…

This study tested a new drug called SL-172154, given alongside one of two standard chemotherapy drugs, in people with ovarian cancer that had stopped responding to platinum-based treatments. The main goals were to find a safe dose and see if the combinations showed early signs of…

This early-stage trial tested a personalized cancer vaccine called TG4050 in patients with ovarian, fallopian tube, or peritoneal cancer who were in remission after initial treatment. The main goal was to check if the vaccine was safe and well-tolerated. Researchers also looked f…

This study aimed to find the best way to prevent severe nausea and vomiting caused by a common chemotherapy regimen for gynecologic cancers like ovarian and cervical cancer. Researchers tested whether adding a drug called aprepitant to the standard two-drug anti-nausea treatment …

This study looked back at medical records to understand how the drug rucaparib was used and performed for patients in Spain with ovarian, fallopian tube, or primary peritoneal cancer. It involved 51 adult women who received the drug through a special access program. The goal was …

This study tested a digital tool designed to help cancer survivors learn about and decide whether to get genetic testing for hereditary cancer risk. Researchers wanted to see if this smart technology was easy to use and if it encouraged more people to get tested. They compared th…

This study aimed to develop a new blood test to better predict if ovarian, peritoneal, or fallopian tube cancer will come back after successful treatment. Researchers collected blood samples from 119 women whose cancer was in remission to look for specific patterns of proteins th…

This study aims to understand how specific genetic changes in ovarian, fallopian tube, or peritoneal cancer affect how the disease progresses and responds to treatment. Researchers will collect medical information and tumor samples from 1500 French patients with advanced-stage ca…